Neuro-Ophthalmic Findings in the Visual Variant of Alzheimers Disease
Ophthalmology 111:376-381, Lee,A.G. &Martin,C.O., 2004
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia
JAMA 314:1242-1254, Cummings, J.L.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Behavioral Effects of Memantine in Alzheimer Disease Patients Receiving Donepezil Treatment
Neurol 67:57-63, Cummings,J.L.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Treatment of Agitation in AD
Neurol 55:1271-1278,1247, Teri,L.,et al, 2000
Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Low Body Weight in Alzheimer's Disease is Associated with Mesial Temporal Cortex Atrophy
Neurol 46:1585-1591, Grundman,M.,et al, 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Rapidly Progressing Atrophy of Medial Temporal Lobe in Alzheimer's Disease
Lancet 343:829-830, Jobst,K.A.,et al, 1994
Management of Neurological Disorders:Dementia
JNNP 57:1451-1456, Rossor,M.N., 1994
A Population-Based Study of Dementia in 85-Year-Olds
NEJM 328:153-158, 203-2051993., Skoog,I.,et al, 1993
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
A Pilot Study of Haloperidol Treatment of Psychosis and Behavioral Disturbance in Alzheimer's Disease
Arch Neurol 46:854-857, Devanand,D.P.,et al, 1989
The Human Kluver-Bucy Syndrome
Neurol 33:1141-1145, Lilly,R.,et al, 1983
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Neuro CPC of MGH
Glioblastoma Multiforme, NEJM 262:413-4161960., , 1960
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018